These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 32892993)

  • 1. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
    Khan SA; Naz A; Qamar Masood M; Shah R
    Am J Cardiol; 2020 Nov; 134():69-73. PubMed ID: 32892993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
    Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP;
    N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inclisiran: A Review in Hypercholesterolemia.
    Frampton JE
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Raal F; Durst R; Bi R; Talloczy Z; Maheux P; Lesogor A; Kastelein JJP;
    Circulation; 2024 Jan; 149(5):354-362. PubMed ID: 37850379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Inclisiran.
    Asbeutah AAA; Asbeutah SA; Abu-Assi MA
    Am J Cardiol; 2020 Aug; 128():218-219. PubMed ID: 32482309
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia.
    Toth PP; Catapano AL; Farnier M; Foody J; Tomassini JE; Jensen E; Polis AB; Hanson ME; Musliner TA; Tershakovec AM
    Am J Cardiol; 2016 Dec; 118(12):1812-1820. PubMed ID: 27756478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
    Ray KK; Kallend D; Leiter LA; Raal FJ; Koenig W; Jaros MJ; Schwartz GG; Landmesser U; Garcia Conde L; Wright RS;
    Eur Heart J; 2022 Dec; 43(48):5047-5057. PubMed ID: 36331315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
    Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
    N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.
    Henry RR; Müller-Wieland D; Taub PR; Bujas-Bobanovic M; Louie MJ; Letierce A; Ginsberg HN
    Diabetes Obes Metab; 2018 Jul; 20(7):1632-1641. PubMed ID: 29493859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
    Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP;
    N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inclisiran, the billion-dollar drug, to lower LDL cholesterol - is it worth it?
    Doggrell SA
    Expert Opin Pharmacother; 2020 Nov; 21(16):1971-1974. PubMed ID: 32749892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia.
    Luo Z; Huang Z; Sun F; Guo F; Wang Y; Kao S; Yang G; Huang J; Li J; Zhao S; He Y
    J Clin Lipidol; 2023; 17(3):392-400. PubMed ID: 37164838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk.
    Rajtar-Salwa R; Bobrowska B; Socha S; Dziewierz A; Siudak Z; Batko J; Bartuś S; Krawczyk-Ożóg A
    Medicina (Kaunas); 2024 Jul; 60(7):. PubMed ID: 39064553
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
    Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
    Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
    Hovingh GK; Lepor NE; Kallend D; Stoekenbroek RM; Wijngaard PLJ; Raal FJ
    Circulation; 2020 Jun; 141(22):1829-1831. PubMed ID: 32479195
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.